OOIR: Observatory of International Research

Papers

(The TQCC of mAbs is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Antibodies to watch in 2022	263
Antibodies to watch in 2021	249
Antibodies to watch in 2023	156
Targeting cancer with antibody-drug conjugates: Promises and challenges	102
BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning	81
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy	67
Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies	66
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	51
Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics	51
In silico proof of principle of machine learning-based antibody design at unconstrained scale	50
Developments and opportunities in continuous biopharmaceutical manufacturing	50
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro	49
Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns	45
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins	45
Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics	43
Coming together at the hinges: Therapeutic prospects of IgG3	40
Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods	39
Fc galactosylation follows consecutive reaction kinetics and enhances immunoglobulin G hexamerization for complement activation	38
Antibodies to watch in 2024	36
Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies	36
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors	35
Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries	35
Calculation of therapeutic antibody viscosity with coarse-grained models, hydrodynamic calculations and machine learning-based parameters	34
Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development	34
Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies	33

A computational method for immune repertoire mining that identifies novel binders from different clonotypes, demonstrated by identifying anti-pertussis toxoid antibodies	33
One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics	33
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy	31
Assessing developability early in the discovery process for novel biologics	30
Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics	29
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays	29
Impact of IgG subclass on molecular properties of monoclonal antibodies	29
Harnessing the potential of machine learning for advancing “Quality by Design” in biomanufacturing	29
Ab-Ligity: identifying sequence-dissimilar antibodies that bind to the same epitope	28
In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom	27
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics	27
Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody	27
Exploration of the antibody–drug conjugate clinical landscape	26
Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis	26
Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2	26
Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings	25
Highly sensitive detection of antibody nonspecific interactions using flow cytometry	25
Strategies for clinical dose optimization of T cell-engaging therapies in oncology	25
Evolution of phage display libraries for therapeutic antibody discovery	24
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	24
Current strategies for detecting functional convergence across B-cell receptor repertoires	24
Data mining patented antibody sequences	24
A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies	23
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV	23
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations	23
Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches	23
A non-clinical comparative study of IL-23 antibodies in psoriasis	23
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRnin vitroandin vivo	23
Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors	21
Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities	21
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	21
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies	21
Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models	20
Versatile and rapid microfluidics-assisted antibody discovery	20
Predicting antibody binders and generating synthetic antibodies using deep learning	20
Blueprint for antibody biologics developability	20
Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation	20
Enhancing the multi-attribute method through an automated and high-throughput sample preparation	19
Ensembles in solution as a new paradigm for antibody structure prediction and design	19
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters	19
In silico prediction of post-translational modifications in therapeutic antibodies	19
Challenges in antibody structure prediction	19
Protective antibodies against human parainfluenza virus type 3 infection	19
Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties	18
Multi-attribute Raman spectroscopy (MARS) for monitoring product quality attributes in formulated monoclonal antibody therapeutics	18
Novel chimeric monoclonal antibodies that block fentanyl effects and alter fentanyl biodistribution in mice	18
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?	18
TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL	18
Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells	17
Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer	17

Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans	17
Enzymatic glycan remodeling–metal free click (GlycoConnect™) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering	17
Reduction of therapeutic antibody self-association using yeast-display selections and machine learning	17
A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention	16
Computational models for studying physical instabilities in high concentration biotherapeutic formulations	16
Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies	15
Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies	15
Rigid monoclonal antibodies improve detection of SARS-CoV-2 nucleocapsid protein	15
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer	15
An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics	15
Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions	15
High concentration formulation developability approaches and considerations	15
Development of QSAR models for in silico screening of antibody solubility	15
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	15
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	15
Mass spectrometry-based multi-attribute method in protein therapeutics product quality monitoring and quality control	14
International nonproprietary names for monoclonal antibodies: an evolving nomenclature system	14
Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names	14
Improved therapeutic index of an acidic pH-selective antibody	14
Technical advancement and practical considerations of LC-MS/MS-based methods for host cell protein identification and quantitation to support process development	14